International Stroke Conference 2008 Preview

BUILDING THE LEADING PRODUCT-BASED NEUROLOGICAL COMPANY Stem Cell Therapeutics Corp. (SCT) is a clinical stage biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patients own resident stem cells. The company’s programs aim to repair neurological function lost due to disease or injury. Learn more about our novel neuro-regenerative therapeutic approach to Stroke while in New Orleans, LA. When: Thursday February 21st, 2008, 7:30pm-9:30pm Where: Hilton New Orleans Riverside, Versailles Ballroom What: Neuro-Regeneration using NTx™-265: A Completely Novel Approach to Stroke Therapy Presentations then Q&A period to follow Dr. Samuel Weiss: Dr. Ludmila Belayev: Dr. Steven C Cramer: Dr. Michael Hill: Neuro-regeneration as a Strategy for Acute CNS Injury Testing Animal Models of Stroke using a Dosing Regimen of hCG and EPO. BETAS: Phase IIa Trial Safety and Early Results with NTx™-265 REGENESIS: a Phase IIb Efﬁcacy Study of NTx™-265 in Stroke Patients This event is not part of the ofﬁcial International Stroke Conference 2008 as planned by the International Stroke Conference Program Committee. Stem Cell Therapeutics TSX-Venture: SSS Suite 1000, 1520 - 4th Street SW Calgary, Alberta, Canada T2R 1H5 T 403.245.5495 F 403.245.5411 Email: info@stemcellthera.com www.stemcellthera.com http://www.stemcellthera.com http://www.stemcellthera.com

Table of Contents Feed for the Digital Edition of International Stroke Conference 2008 Preview

Program Schedule Exhibit Hall Map Exhibitor List Program Info

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.